Fresh thinking is redefining where and how early-phase clinical trials take shape. In this edition: LATAM aims to quadruple its clinical trial footprint.
clinical trial · FDA · MedTech · data
Fresh thinking is redefining where and how early-phase clinical trials take shape. In this edition:
Explore how strategy, science, and regions are converging.
Latin America is making a strategic push to become a major global hub for clinical research. The region’s participation in global clinical trials is currently just 2%, but local industry leaders believe it can grow to 8% — or higher — in the coming years. Cost advantages, fast approvals, and diverse patient populations are key drivers in this expansion, especially as global sponsors seek alternatives to saturated markets in the U.S. and Europe. Why It Matters: As sponsors look for cost-effective and regulatory-friendly environments for early-phase trials, Latin America’s positioning could reshape feasibility strategies — especially for Medtech and Biopharma sponsors exploring first-in-human or pilot studies.
Community Health Workers (CHWs) are emerging as a powerful, ROI-driven tool for Medtech clinical trials — especially in Latin America. When integrated strategically, CHWs can improve recruitment speed, patient retention, data quality, and even post-trial market intelligence. A four-pillar model shows returns of up to 305%, making a strong case for their inclusion in early-phase study designs. Bottom Line: CHWs not only build trust and improve participant engagement — they also enhance operational efficiency and site performance in regions where patient access and follow-up can be challenging.
Does Your Company Need Accelerated First-in-Human Clinical Trial Results?
Overcome the complex landscape of first-in-human clinical trials with confidence. Whether you’re advancing Medtech devices, Biopharma therapies, or Radiopharmaceutical innovations, bioaccess® delivers expert solutions to help you succeed.
Schedule Your First-in-Human Trial Consult
The FDA just released its regulatory guidance priorities for 2026 — and it’s a clear signal to Medtech and Biopharma sponsors: smarter trials, faster approvals, and more patient-centric approaches are on the horizon. From finalizing guidance on real-world evidence (RWE) to new frameworks for AI-enabled software and patient preference data, the agency is setting the stage for a more dynamic and data-driven regulatory environment.
Womens health is seeing a surge in Medtech innovation and investor backing. From self-collected cervical screening to breakthrough devices for postpartum bleeding and endometriosis, the sector is finally gaining serious traction — and global reach. Quick Highlights:
The UKs EJS ACT-PD trial is reshaping how neurodegenerative research gets done. Built as a platform trial, it can test multiple treatments simultaneously, using a shared placebo group and flexible trial arms. With virtual visits, home drug delivery, and patient co-design, it’s a new gold standard in trial innovation. What Makes This Different:
← All Global Trial Accelerators editions · Contact bioaccess®